Other Earnings and Cash Flow Stats:
Alvotech ( ALVO ) Net Income TTM ($MM) is -441.45
Alvotech ( ALVO ) Operating Income TTM ($MM) is -45.44
Alvotech ( ALVO ) Owners' Earnings Annual ($MM) is 0.00
Alvotech ( ALVO ) Current Price to Owners' Earnings ratio is 0.00
Alvotech ( ALVO ) EBITDA TTM ($MM) is -15.57
Alvotech ( ALVO ) EBITDA Margin is 18.22%
Capital Allocation:
Alvotech ( ALVO ) has paid 0.00 dividends per share and bought back -34.232996 million shares in the past 12 months
Alvotech ( ALVO ) has increased its debt by 168.477 million USD in the last 12 months
Capital Structure:
Alvotech ( ALVO ) Interest-bearing Debt ($MM) as of last quarter is 1192
Alvotech ( ALVO ) Annual Working Capital Investments ($MM) are 117
Alvotech ( ALVO ) Book Value ($MM) as of last quarter is -344
Alvotech ( ALVO ) Debt/Capital as of last quarter is -347%
Other Balance Sheet Stats:
Alvotech ( ALVO ) has 118 million in cash on hand as of last quarter
Alvotech ( ALVO ) has 160 million of liabilities due within 12 months, and long term debt 1028 as of last quarter
Alvotech ( ALVO ) has 301 common shares outstanding as of last quarter
Alvotech ( ALVO ) has 0 million USD of preferred stock value
Academic Scores:
Alvotech ( ALVO ) Altman Z-Score is -0.60 as of last quarter
Alvotech ( ALVO ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Alvotech ( ALVO ) largest shareholder is JANE STREET GROUP, LLC owning 56295 shares at 0.71 ($MM) value
(an insider) shares of Alvotech ( ALVO ) for the amount of $ on
64.01% of Alvotech ( ALVO ) is held by insiders, and 6.04% is held by institutions
Alvotech ( ALVO ) went public on 2022-06-16
Other Alvotech ( ALVO ) financial metrics:
FCF:-301.21
Unlevered Free Cash Flow:0.00
EPS:-0.15
Operating Margin:12.37
Gross Profit Margin:61.31
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:13.26
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Alvotech ( ALVO ) :
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
DISCLAIMER
This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.